Entrada Therapeutics, Inc. (TRDA) insider trading

By person

10 insiders · 61 transactions

5.8×

Dipal Doshi holds 5.8 times base salary in stock. $3.69M of shares against $635.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Dipal Doshi last reported holding, valued at $7.13, the price Common Stock was last bought or sold at on the open market here, on 9 Sep 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Kush Parmar

Director

—

$3.65M (6)

−$3.65M

2,691,337

6.91%

$19.19M

−18.8%

MPM BioVentures 2014, L.P.

10% owner

—

$3.60M (12)

−$3.60M

8,203,463

21.07%

$58.49M

−6.2%

Mpm Bioventures 2018, L.p.

10% owner

—

$3.60M (12)

−$3.60M

8,203,463

21.07%

$58.49M

−6.2%

5AM Ventures V, L.P. entity

10% owner

—

$3.00M (5)

−$3.00M

3,877,094

9.96%

$27.64M

−12.1%

Baker Bros. Advisors LP entity

10% owner

$1.61M (16)

—

+$1.61M

4,691,392

12.05%

$33.45M

+4.6%

Kory James Wentworth

Chief Financial Officer

—

$433.58K (5) scheduled

−$433.58K

117,277

0.3012%

$836.19K

+53.3%

Nathan J Dowden

President & COO

—

$425.72K (3) scheduled

−$425.72K

196,060

0.5035%

$1.40M

+56.7%

Natarajan Sethuraman

President, Research & Develop.

—

$398.81K (1) scheduled

−$398.81K

214,238

0.5502%

$1.53M

+29.8%

Bernhardt G Zeiher

Director

$29.32K (1)

—

+$29.32K

5,000

0.0128%

$35.65K

—

Dipal Doshi

CEO

—

517,290

1.33%

$3.69M

+58.8%

Entrada Therapeutics, Inc.

What the insiders did Net selling

By person